| Date Filed | Type | Description |
| 09/26/2023 |
8-K
| Termination of a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 07/20/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/14/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 07/14/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 07/14/2023 |
8-K/A
| Quarterly results |
| 07/13/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 07/13/2023 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I... |
| 07/13/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/10/2023 |
SC 13G
| PFIZER INC reports a 7.1% stake in CARIBOU BIOSCIENCES, INC. |
| 07/06/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, ... |
| 06/16/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 06/09/2023 |
4
| Haurwitz Rachel E. (President and CEO) has filed a Form 4 on Caribou Biosciences, Inc.|
Txns:
| Exercised 10,000 options to buy
@ $2.96, valued at
$29.6k
|
|
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 04/04/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 03/29/2023 |
8-K
| Quarterly results |
| 03/29/2023 |
8-K
| Quarterly results |
| 03/24/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/22/2023 |
4
| Haurwitz Rachel E. (President and CEO) has filed a Form 4 on Caribou Biosciences, Inc.|
Txns:
| Exercised 10,000 options to buy
@ $2.96, valued at
$29.6k
|
|
| 03/09/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/09/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/09/2023 |
8-K
| Quarterly results |
| 02/23/2023 |
4
| Haurwitz Rachel E. (President and CEO) has filed a Form 4 on Caribou Biosciences, Inc.|
Txns:
| Granted 510,500 options to buy
@ $6.12, valued at
$3.1M
|
|
| 02/23/2023 |
4
| Kanner Steven (Chief Scientific Officer) has filed a Form 4 on Caribou Biosciences, Inc.|
Txns:
| Granted 131,000 options to buy
@ $6.12, valued at
$801.7k
|
|
| 02/23/2023 |
4
| Richardson-Heron Dara (Director) has filed a Form 4 on Caribou Biosciences, Inc.|
Txns:
| Granted 21,500 options to buy
@ $6.12, valued at
$131.6k
|
|
| 02/23/2023 |
4
| Khan Ruhi Ahmad (Chief Business Officer) has filed a Form 4 on Caribou Biosciences, Inc.|
Txns:
| Granted 131,000 options to buy
@ $6.12, valued at
$801.7k
|
|
| 02/23/2023 |
4
| Sacks Natalie (Director) has filed a Form 4 on Caribou Biosciences, Inc.|
Txns:
| Granted 21,500 options to buy
@ $6.12, valued at
$131.6k
|
|
| 02/23/2023 |
4
| Braunstein Scott (Director) has filed a Form 4 on Caribou Biosciences, Inc.|
Txns:
| Granted 21,500 options to buy
@ $6.12, valued at
$131.6k
|
|
| 02/23/2023 |
4
| GUGGENHIME ANDREW (Director) has filed a Form 4 on Caribou Biosciences, Inc.|
Txns:
| Granted 21,500 options to buy
@ $6.12, valued at
$131.6k
|
|
| 02/23/2023 |
4
| MCCLUNG BARBARA G (Chief Legal Officer) has filed a Form 4 on Caribou Biosciences, Inc.|
Txns:
| Granted 131,000 options to buy
@ $6.12, valued at
$801.7k
|
|
| 02/23/2023 |
4
| Rizvi Syed Ali-aamir (Chief Medical Officer) has filed a Form 4 on Caribou Biosciences, Inc.|
Txns:
| Granted 131,000 options to buy
@ $6.12, valued at
$801.7k
|
|
| 02/23/2023 |
4
| Zheng Ran (Director) has filed a Form 4 on Caribou Biosciences, Inc.|
Txns:
| Granted 21,500 options to buy
@ $6.12, valued at
$131.6k
|
|
|